221 related articles for article (PubMed ID: 8699005)
1. In vivo CTL immunity can be elicited by in vitro reconstituted MHC/peptide complex.
Sakita I; Hörig H; Sun R; Wang F; Nathenson SG
J Immunol Methods; 1996 Jun; 192(1-2):105-15. PubMed ID: 8699005
[TBL] [Abstract][Full Text] [Related]
2. Peptide-priming of cytolytic T cell immunity in vivo using beta 2-microglobulin as an adjuvant.
Rock KL; Fleischacker C; Gamble S
J Immunol; 1993 Feb; 150(4):1244-52. PubMed ID: 8381832
[TBL] [Abstract][Full Text] [Related]
3. Peptide loading of empty major histocompatibility complex molecules on RMA-S cells allows the induction of primary cytotoxic T lymphocyte responses.
De Bruijn ML; Schumacher TN; Nieland JD; Ploegh HL; Kast WM; Melief CJ
Eur J Immunol; 1991 Dec; 21(12):2963-70. PubMed ID: 1660811
[TBL] [Abstract][Full Text] [Related]
4. Possible mechanisms by which the H-2Kbm3 mutation may decrease cytotoxic T-lymphocyte recognition of vesicular stomatitis virus nucleoprotein antigen.
Bowman MR; Lyles DS; Parce JW
J Virol; 1987 Jun; 61(6):1992-8. PubMed ID: 3033326
[TBL] [Abstract][Full Text] [Related]
5. A viral peptide can mimic an endogenous peptide for allorecognition of a major histocompatibility complex class I product.
Guimezanes A; Schumacher TN; Ploegh HL; Schmitt-Verhulst AM
Eur J Immunol; 1992 Jun; 22(6):1651-4. PubMed ID: 1318201
[TBL] [Abstract][Full Text] [Related]
6. Cytolytic T lymphocytes from the BALB/c-H-2dm2 mouse recognize the vesicular stomatitis virus glycoprotein and are restricted by class II MHC antigens.
Browning MJ; Huang AS; Reiss CS
J Immunol; 1990 Aug; 145(3):985-94. PubMed ID: 1695651
[TBL] [Abstract][Full Text] [Related]
7. Failure or success in the restoration of virus-specific cytotoxic T lymphocyte response defects by dendritic cells.
Kast WM; Boog CJ; Roep BO; Voordouw AC; Melief CJ
J Immunol; 1988 May; 140(9):3186-93. PubMed ID: 2834454
[TBL] [Abstract][Full Text] [Related]
8. IFN-gamma-induced recognition of the antigen-processing variant CMT.64 by cytolytic T cells can be replaced by sequential addition of beta 2 microglobulin and antigenic peptides.
Jefferies WA; Kolaitis G; Gabathuler R
J Immunol; 1993 Sep; 151(6):2974-85. PubMed ID: 8397249
[TBL] [Abstract][Full Text] [Related]
9. Presentation of a horse cytochrome c peptide by multiple H-2b class I major histocompatibility complex (MHC) molecules to C57BL/6- and bm1-derived cytotoxic T lymphocytes: presence of a single MHC anchor residue may confer efficient peptide-specific CTL recognition.
Sheil JM; Schell TD; Shepherd SE; Klimo GF; Kioschos JM; Paterson Y
Eur J Immunol; 1994 Sep; 24(9):2141-9. PubMed ID: 7522163
[TBL] [Abstract][Full Text] [Related]
10. Point mutations in the beta chain CDR3 can alter the T cell receptor recognition pattern on an MHC class I/peptide complex over a broad interface area.
Goyarts EC; Vegh Z; Kalergis AM; Hörig H; Papadopoulos NJ; Young AC; Thomson CT; Chang HC; Joyce S; Nathenson SG
Mol Immunol; 1998 Jul; 35(10):593-607. PubMed ID: 9823758
[TBL] [Abstract][Full Text] [Related]
11. Alterations in TCR-MHC contacts subsequent to cross-recognition of class I MHC and singly substituted peptide variants.
Ono T; DiLorenzo TP; Wang F; Kalergis AM; Nathenson SG
J Immunol; 1998 Nov; 161(10):5454-63. PubMed ID: 9820521
[TBL] [Abstract][Full Text] [Related]
12. Thymus dictates major histocompatibility complex (MHC) specificity and immune response gene phenotype of class II MHC-restricted T cells but not of class I MHC-restricted T cells.
Kast WM; de Waal LP; Melief CJ
J Exp Med; 1984 Dec; 160(6):1752-66. PubMed ID: 6096476
[TBL] [Abstract][Full Text] [Related]
13. Role of de novo protein synthesis in target cells recognized by cytotoxic T lymphocytes specific for vesicular stomatitis virus.
Roscoe DM; Ishikawa K; Lyles DS
J Virol; 1991 Dec; 65(12):6856-61. PubMed ID: 1658379
[TBL] [Abstract][Full Text] [Related]
14. Efficient MHC class I-peptide binding is required but does not ensure MHC class I-restricted immunogenicity.
Feltkamp MC; Vierboom MP; Kast WM; Melief CJ
Mol Immunol; 1994 Dec; 31(18):1391-401. PubMed ID: 7823965
[TBL] [Abstract][Full Text] [Related]
15. Characterization of dual-reactive H-2Kb-restricted anti-vesicular stomatitus virus and alloreactive cytotoxic T cells.
Sheil JM; Bevan MJ; Lefrancois L
J Immunol; 1987 Jun; 138(11):3654-60. PubMed ID: 3035010
[TBL] [Abstract][Full Text] [Related]
16. Heat-inactivated Sendai virus can enter multiple MHC class I processing pathways and generate cytotoxic T lymphocyte responses in vivo.
Liu T; Zhou X; Orvell C; Lederer E; Ljunggren HG; Jondal M
J Immunol; 1995 Apr; 154(7):3147-55. PubMed ID: 7897204
[TBL] [Abstract][Full Text] [Related]
17. Broad recognition of cytotoxic T cell epitopes from the HIV-1 envelope protein with multiple class I histocompatibility molecules.
Shirai M; Pendleton CD; Berzofsky JA
J Immunol; 1992 Mar; 148(6):1657-67. PubMed ID: 1371784
[TBL] [Abstract][Full Text] [Related]
18. Antigen processing mutant T2 cells present viral antigen restricted through H-2Kb.
Zhou X; Glas R; Liu T; Ljunggren HG; Jondal M
Eur J Immunol; 1993 Aug; 23(8):1802-8. PubMed ID: 8393799
[TBL] [Abstract][Full Text] [Related]
19. V beta 5+ T cell receptors skew toward OVA+H-2Kb recognition.
Dillon SR; Jameson SC; Fink PJ
J Immunol; 1994 Feb; 152(4):1790-801. PubMed ID: 8120388
[TBL] [Abstract][Full Text] [Related]
20. In vivo treatment with a MHC class I-restricted blocking peptide can prevent virus-induced autoimmune diabetes.
von Herrath MG; Coon B; Lewicki H; Mazarguil H; Gairin JE; Oldstone MB
J Immunol; 1998 Nov; 161(9):5087-96. PubMed ID: 9794447
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
